化合物 Sulindac sodium|T61585|TargetMol

价格	￥10600	￥17500	￥13800
包装	25mg	100mg	50mg

最小起订量	1mg
发货地	上海
更新日期	2025-11-17

QQ交谈微信洽谈

产品详情

中文名称:化合物 Sulindac sodium	英文名称:Sulindac sodium
CAS:63804-15-9	品牌: TargetMol
产地: 美国	保存条件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
产品类别: 抑制剂
货号: T61585

Product Introduction

Bioactivity

名称	Sulindac sodium
描述	Sulindac (sodium) (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac (sodium) is used to reduce pain, swelling, and joint stiffness from arthritis. Sulindac is also used for the research of arthritis of the spine, gouty arthritis. Sulindac (sodium), as an immunomodulatory agent, can downregulate PD-L1 through the blockade of NF-κB signaling and modulates the response of pMMR colorectal cancer (CRC) to anti-PD-L1 immunotherapy, inhibits the development and progression of colorectal cancer CRC. Sulindac (sodium) also inhibits TGF-β1- induced epithelial-mesenchymal transition (EMT) and suppresses lung cancer cell migration and invasion via downregulation of SIRT1 [1] [2].
体外活性	Sulindac (sodium) (MK-231 (sodium)) is effective in preventing TGF-β1-induced EMT, as indicated by upregulation of the epithelial marker, E-cadherin, and downregulation of mesenchymal markers and transcription factors. Sulindac (sodium) (MK-231 (sodium)) can inhibit TGF-β1-enhanced migration and invasion of A549 cells. SIRT1 downregulation enhances the reversal of TGF-β1-induced EMT by sulindac (sodium) and SIRT1 upregulation promoted TGF-β1-induced EMT [1]. Western Blot Analysis [1] Cell Line: A549 cells Concentration: 500 μM Incubation Time: 48 h Result: Inhibit transforming growth factor (TGF)-β1-induced epithelial-mesenchymal transition in A549 cells. Immunofluorescence [1] Cell Line: A549 cells Concentration: 500 μM Incubation Time: 48 h Result: Reversed SIRT-1 expression by TGF-β1 and inhibited the TGF-β1-induced cadherin switch. Cell Migration Assay [1] Cell Line: A549 cells Concentration: 500 μM Incubation Time: 48 h Result: Inhibited migration, decreased resistance co-treatment with TGF-β1. Cell Invasion Assay [1] Cell Line: A549 cells Concentration: 500 μM Incubation Time: 40 h; 48 h Result: Could effectively inhibit the TGF- β1-induced increase in invasion by lung cancer cells.
体内活性	Sulindac (sodium) (MK-231 (sodium)) (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) shows a significant reduction in tumor volume and increases infiltration of CD8+ T lymphocytes in the tumor tissues when treated with combination therapy. Sulindac (sodium) (MK-231 (sodium)) (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) can downregulate PD-L1 by blocking NF-κB signaling, which in turn led to a decrease in exosomal P. Sulindac (sodium) (MK-231 (sodium)) (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) leads to increased availability of PD-L1 Ab by downregulating PD-L1 in combination therapy. SulindacSulindac (sodium) (MK-231 (sodium)) has not a systemic inhibitory effect on prostaglandin E2 (PGE2) in low-dose does [2]. Animal Model: CT26 syngeneic mouse tumor model [2] Dosage: 15 mg/kg; 7.5 mg/kg Administration: 15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1) Result: Downregulated PD-L1 through the blockade of NF-κB signaling and modulate the response of pMMR CRC to anti-PD-L1 immunotherapy. Animal Model: CT26 syngeneic mouse tumor model [2] Dosage: 15 mg/kg; 7.5 mg/kg Administration: 15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1) Result: Downregulated PD-L1 through the blockade of NF-κB signaling and modulate the response of pMMR CRC to anti-PD-L1 immunotherapy. Cound effectively inhibit PD-L1 with no significant systematic toxicity.
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
相关产品	sodium lauroyl-α-hydroxyethyl sulfonate \| Ethyl palmitate \| Anethole \| Diallyl disulfide \| Glucosamine \| Sodium salicylate \| Methylamine HCl \| Naringin dihydrochalcone \| Fumaric acid \| Kojic acid \| N,N-Dimethylacetamide \| Diethylmaleate

关键字： Sulindac sodium|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	2013-04-18 （13年）	注册资本	589.8595万人民币
员工人数	100-500人	年营业额	￥ 1亿以上
主营行业	中间体,天然产物,生物化工,化学试剂,生物技术服务	经营模式	贸易,工厂,试剂,定制,服务

TargetMol中国（陶术生物）

VIP 2年

公司成立：13年
注册资本：589.8595万人民币
企业类型：有限责任公司(自然人投资或控股)
主营产品：抑制剂&激动剂，天然产物，重组蛋白，化合物库，技术服务
公司地址：上海市静安区江场三路238号8楼

进入店铺

询盘

店内推荐

化合物 JP7|T32313|TargetMol

￥10600

化合物 HDAC/JAK/BRD4-IN-1|T79768|TargetMol

￥17500

化合物 Rosuvastatin zinc salt|T81257|TargetMol

询价

化合物 Sulindac sodium|T61585|TargetMol相关厂家报价

产品名称	价格		公司名称	报价日期
化合物 IFETROBAN SODIUM	询价	VIP4年	江苏迈凯生物科技有限公司	2025-10-28
化合物 D2157	询价	VIP6年	山东沃德森生物科技有限公司	2025-11-25
化合物 OSIVELOTOR	询价	VIP2年	青岛恺润生物医药科技有限公司	2025-11-06

内容声明:
以上所展示的信息由商家自行提供，内容的真实性、准确性和合法性由发布商家负责。商家发布价格指该商品的参考价格，并非原价，该价格可能随着市场变化，或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格，请咨询商家，以实际成交价格为准。请意识到互联网交易中的风险是客观存在的